MedTrace Logo

Prospective Study for the FOLLOW-UP of Human Monkeypox Cases and Smallpox Vaccinees at Risk

NCT05879965 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 345

Last updated 2026-03-19

No results posted yet for this study

Summary

The goal of this observational study is to describe possible physical and psychological sequelae after an mpox infection and to evaluate the longevity of B- and T-cell immune responses in former mpox patients and vaccine recipients.

The main questions it aims to answer are:

* Are there any physical or pschological sequelae after mpox infection?
* Is the humoral and/or cellular immune response to MPOX (or vaccinia) virus) durable?
* Do the patients develop strong local immunity in comparison to systemic immunity?
* How long is the virus still detectable in semen, saliva or the ano-rectal region?

Participants will answer a questionnaire, samples with blood, saliva and semen as well as anal swabs will be collected. Follow-up visits 8, 16 and 24, 36, 48, and 60 months after infection or vaccination are planned.

A healthy control group will be recruited in our HIV-PrEP clinic.

Conditions

  • Monkeypox

Sponsors & Collaborators

  • Institute of Tropical Medicine, Belgium

    lead OTHER

Principal Investigators

  • Nicole Berens-Riha, PhD · Institute of Tropical Medicine

  • Laurens Liesenborghs, PhD · Institute of Tropical Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-06
Primary Completion
2027-10-31
Completion
2028-06-30

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05879965 on ClinicalTrials.gov